上皮损伤与炎症表型指导ARDS个体化通气:LIVE试验二次分析
该研究为LIVE试验二次分析,纳入259例有血浆sRAGE测量的ARDS患者,比较肺复张与低PEEP策略。结果显示,基线sRAGE可识别肺复张对90天死亡率疗效的异质性,而炎症表型仅与预后相关,不能识别疗效异质性。
要点
- 高基线sRAGE的ARDS患者接受肺复张与90天死亡率降低相关。
- 低基线sRAGE患者接受肺复张与90天死亡率升高相关。
- 炎症表型与90天死亡率相关,但未识别肺复张疗效异质性。
核心结论
- 在ARDS中,血浆sRAGE评估的上皮损伤可识别肺复张治疗效应的异质性。
- 炎症表型对死亡率有预后价值,但未识别肺复张治疗效应的异质性。
研究设计与样本
- 研究为LIVE试验的二次分析,纳入259例有血浆sRAGE测量的ARDS患者。
- LIVE试验比较肺复张与低PEEP策略在局灶性或非局灶性ARDS患者中的效果。
- 基线sRAGE以2,440 pg/mL二分分为高、低组,炎症表型用基于IL-8、sTNFR1和碳酸氢盐的简约模型识别。
- 主要结局为90天死亡率,次要结局为至第6天的sRAGE轨迹;采用逆概率加权和加权Cox模型,sRAGE轨迹用联合模型评估。
主要发现
- 高血浆sRAGE与无局灶性ARDS中度相关(r=0.26;P<.001),炎症表型无此相关。
- 治疗效应随基线sRAGE变化(交互P=.006),但不随炎症表型变化(交互P=.56)。
- 高炎症表型与90天死亡率相关(57% vs 26%;P<.001)。
- 高sRAGE患者中,肺复张与90天死亡率降低相关(HR=0.41;95%CI 0.18-0.93;P=.033)。
- 低sRAGE患者中,肺复张与死亡率升高相关(HR=3.27;95%CI 1.06-10.1;P=.039)。
关键数值与推荐
- 基线sRAGE二分阈值为2,440 pg/mL。
- 高sRAGE患者肺复张的90天死亡率HR=0.41(95%CI 0.18-0.93;P=.033)。
- 低sRAGE患者肺复张的90天死亡率HR=3.27(95%CI 1.06-10.1;P=.039)。
- 高炎症表型90天死亡率为57%,低炎症表型为26%(P<.001)。
临床怎么用
- 对ARDS患者,可考虑检测血浆sRAGE以辅助识别可能从肺复张中获益的高上皮损伤亚组。
- 低基线sRAGE患者接受肺复张可能有害,应避免常规使用。
- 炎症表型可用于预后评估,但不宜用于选择肺复张策略。
局限性
- 本研究为二次分析,结果需前瞻性验证。
- 仅纳入有血浆sRAGE测量的患者,可能存在选择偏倚。
- 敏感性分析未使用逆概率加权,但方向一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend against systematic lung recruitment strategies in ARDS. Soluble receptor for advanced glycation end products (sRAGE), an alveolar epithelial injury plasmatic biomarker, and inflammatory phenotypes may guide personalized approaches. RESEARCH QUESTION: Does baseline sRAGE or inflammatory phenotype identify heterogeneity in the treatment effect of lung recruitment on mortality in ARDS? STUDY DESIGN AND METHODS: This analysis included 259 patients with plasma sRAGE measurements from the original Lung Imaging for Ventilator Setting (LIVE) trial that compared lung recruitment with low positive end-expiratory pressure strategies in patients with focal or non-focal ARDS. Baseline sRAGE levels were dichotomized at 2,440 pg/mL into high and low groups. Inflammatory phenotypes were identified using a validated parsimonious model (IL-8, soluble tumor necrosis factor receptor 1, and bicarbonate). The primary and secondary outcomes were 90-day mortality and sRAGE trajectory until day 6. Inverse probability weighting and weighted Cox models were used; sRAGE trajectories were assessed using joint models. RESULTS: High plasma sRAGE (r = 0.26; P < .001), but not the inflammatory phenotype, was moderately correlated with non-focal ARDS. The treatment effect varied by baseline sRAGE (interaction P = .006), but not by inflammatory phenotype (interaction P = .56); however, the hyperinflammatory phenotype was associated with 90-day mortality (57% vs 26%; P < .001). Among patients with high sRAGE levels, lung recruitment was associated with lower 90-day mortality (hazard ratio, 0.41; 95% CI, 0.18-0.93; P = .033); among patients with low sRAGE levels, it was associated with higher mortality (hazard ratio, 3.27; 95% CI, 1.06-10.1; P = .039). Lung recruitment was associated with different sRAGE slopes compared with low positive end-expiratory pressure, with effect modification by baseline sRAGE. Lung recruitment was associated with a steeper decline in sRAGE among patients with high baseline sRAGE levels (interaction P < .001), and with a slower decline among patients with low baseline sRAGE levels (interaction P = .038). Inflammatory phenotypes did not identify heterogeneity of treatment effect. Sensitivity analyses without inverse probability weighting were directionally consistent. INTERPRETATION: Our results show that, in ARDS, epithelial injury assessed by plasma sRAGE may identify heterogeneity of treatment effect with lung recruitment, whereas inflammatory phenotypes remain prognostic for mortality.
引用
- Pensier J, Renard-Triché L, Theilliere C, et al. Epithelial Injury and Inflammatory Phenotypes for Personalized Ventilation in ARDS: Secondary Analysis of the Lung Imaging for Ventilator Setting Trial. Chest. 2026. PMID: 42777910. doi:10.1016/j.chest.2026.08.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。